Skip to content

Clinical and Biological Characterization of Patients and Collection of Samples

Tricho-hepato-enteric Syndrome: From Abnormal RNA Decay to Disease Clinical and Biological Characterization of Patients and Collection of Samples -THE-RNA

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04499040
Acronym
THE-RNA
Enrollment
100
Registered
2020-08-05
Start date
2020-09-01
Completion date
2023-12-31
Last updated
2020-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tricho Hepato Enteric Syndrome

Brief summary

Objectives: Collect clinical and biological data about patients with SD/THE, collect samples of patients; create a secure on line database to collect worldwide data about SD/THE Partners : APHM, HCL, APHP Currently10 patients (8 with TTC37 mutations and 2 with SKIV2l mutations) present a SD/THE and are managed in France in 5 different centers (Marseille, Paris Trousseau, Paris Necker, Paris Robert Debrés, and Lyon). Most of them are followed in hepato-gastro-enterology units for their intractable diarrhea. Three aspects of the disease: intractable diarrhea, immune defect and liver disease are responsible for the main part of the burden of the disease .For each aspect, the investigators will propose a close follow-up with collection of clinical, biochemical, functional and microbial data. Collect of clinical date: during a programmed consultation clinical data about symptom will be collected twice a year. A detailed form will be used for better delineation of the symptoms. These data included growth, symptom (diarrhea, pain …), and clinical signs. Most of these children have recurrent sample for follow up. During them some blood will be take for study the immune side but also the platelet function.

Interventions

BIOLOGICALBlood sample

Blood samples to assess biological parameters such as:

Microbiota analysis

BEHAVIORALNeuropsychological

Neuropsychological assessment

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* patient \< 18 year-old * patients with SD/THE control group : * patients with tufting enteropathy and short bowel syndrome.

Exclusion criteria

* child among whom the parents or the legal representatives refused that their child participates in this study

Design outcomes

Primary

MeasureTime frameDescription
Assessment of detailed clinical characteristics of the phenotype of Tricho-hepato-enteric syndrome3 yearsExistence or absence of 9 clinical signs suggestive of Tricho-hepato-enteric syndrome, to know: * neonatal characteristics, * existence or not of the 9 clinical signs suggestive of the disease, * initial symptoms and chronology leading to the diagnosis, * organ damage, * nutrition, * treatment, * growth, * dermatological evaluation, * hepatic evaluation, * neuropsychological evaluation (score of WPPSI-III, WISC-IV, WAIS-IV), * quality of life scale (VSPA in children between 3 and 17 years old and WHOQUOL in adults), * self-report anxiety scale (STAI in children over 8 years)

Countries

France

Contacts

Primary ContactAlexandre FABRE
alexandre.fabre@ap-hm.fr491382747
Backup ContactDRS AP-HM, Sponsor
drci@ap-hm.fr491382747

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026